Product
Supplier
Encyclopedia
Inquiry
Jinlan 98+ EP/BP/USP Zanubrutinib buy - large image1
Jinlan 98+ EP/BP/USP Zanubrutinib buy - image1

Jinlan 98+ EP/BP/USP Zanubrutinib

Unit Price: Get Latest Price
CAS No.:

1691249-45-2

Grade:

medical grade

Content:

98%

Port:

Shanghai/Ningbo/Qingdao

Brand:

Jinlan

Packaging:

25kg/Cardboard Drum

Sample Available:

Yes

Price valid (until):

2026-04-15

Company Type:
Trader
Location:
China
Payment Terms:
100% TT in advance
Average Lead Time:
275 days
Qualification:
Main Products:

Peptides,API,Intermediate

  • Product Details

  • Seller Information

  • Description


      Product Detail  


    Zanubrutinib

    • CAS: 1691249-45-2
    • Molecular Formula: C₂₇H₃₄N₆O₃
    • Molecular Weight: 482.60 g/mol
    • Synonyms: Brukinsa, BGB-3111
    • Form: Solid powder
    • Storage: Store at 2–8°C under inert atmosphere
    • Description: Bruton’s tyrosine kinase (BTK) inhibitor. Used in mantle cell lymphoma and chronic lymphocytic leukemia.
    ECHEMI Editorial Reference
    Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma that is associated with early relapse, poor clinical outcomes, and long-term survival. BTK is an enzyme that plays a role in oncogenic signalling pathways, where it promotes the survival and proliferation of malignant B cells. Compared to the first-generation BTK inhibitor [ibrutinib], zanubrutinib displays higher potency and selectivity for BTK with fewer off-target effects. Due to this enhanced selectivity towards BTK, zanubrutinib belongs to the second-generation BTK inhibitor drug group that also includes [acalabrutinib], which was approved by the FDA in 2017. Zanubrutinib was granted accelerated approval by the FDA in November 2019 based on clinical trial results that demonstrated an 84% overall response rate from zanubrutinib therapy in patients with MCL, which measures the proportion of patients in a trial whose tumour is entirely or partially destroyed by a drug. It is currently marketed under the trade name BRUKINSA™ and is available as oral capsules.|Zanubrutinib is a Kinase Inhibitor. The mechanism of action of zanubrutinib is as a Bruton's Tyrosine Kinase Inhibitor.|Zanubrutinib is an oral inhibitor of Bruton’s tyrosine kinase that is used in the therapy of refractory mantle cell lymphoma. Zanubrutinib has been associated with a low rate of serum enzyme elevations during therapy, but has not been linked to cases of clinically apparent acute liver injury although it may pose a risk for reactivation of hepatitis B in susceptible patients.|Zanubrutinib is an inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, zanubrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways, which leads to the inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B-lymphocyte development, activation, signaling, proliferation and survival.
    Zanubrutinib, a second-generation BTK inhibitor discovered and developed by BeiGene in China, has been approved by the FDA (in 2019) for treating chronic lymphocytic leukemia (CLL) and certain other indications. Zanubrutinib has lower toxicity and better efficacy than ibrutinib. It is in direct competition with AstraZeneca’s acalabrutinib for the $12 billion blood cancer market currently dominated by the first-in-class BTK inhibitor ibrutinib.
    Class: non-receptor tyrosine kinaseTreatment: MCL, MZL, WMOral bioavailability = 15%Elimination half-life = 3.3 hProtein binding = 94%

    Basic Info
    Product Name:

    Zanubrutinib

    Other Name:

    Zanubrutinib;anubrutinib;BGB-3111(Zanubrutinib);The BTK inhibitor;Zanubrutinib (BGB-3111);BGB-3111;ZANUBRUTINIB;BGB 3111;BGB3111;(S)-7-(1-Acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide;Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 4,5,6,7-tetrahydro-7-[1-(1-oxo-2-propen-1-yl)-4-piperidinyl]-2-(4-phenoxyphenyl)-, (7S)-

    CAS No.:

    1691249-45-2

    Molecular Formula:

    C27H29N5O3

    InChIKeys:

    RNOAOAWBMHREKO-QFIPXVFZSA-N

    Molecular Weight:

    471.55

    Exact Mass:

    471.55

    EC Number:

    202-303-5

    UNII:

    AG9MHG098Z

    NCI Thesaurus Code:

    C141428

    Color/Form:

    White to off-white

    ATC Code:

    L - Antineoplastic and immunomodulating agents

    Categories:

    Other Chemical Drugs

    Characteristics
    Density:

    1.33±0.1 g/cm3(Predicted)

    Boiling Point:

    713.4±60.0 °C(Predicted)

    PKA:

    15.35±0.40(Predicted)

    Critical Temperature & Pressure:

    Store at -20°C

  • Seller Information
    Business Type:

    Trader

    Main Products:

    Peptides,API,Intermediate

    Location:

    Room 606, Building 1, Fu Yi Commercial Center, Shangcheng District, Hangzhou City, Zhejiang Province - 1

    Payment Terms:

    100% TT in advance

    Average lead Time:

    275 days

    Total Annual Revenue:

    $1 million-$2.5 million

    Total Employees:

    51-100

    Year of Establishment:

    2020

    Hangzhou Jinlan Pharm-Drugs Technology Co., Ltd (with its export company Hangzhou Royall Import & Export Co.,Ltd.) is located in Hangzhou, Zhejiang Province. Neighboring Ningbo port, Shanghai port, Hangzhou Xiaoshan Int' l Airport and Shanghai Pudong Int' l Airport, the transportation and production environment are excellent. JINLAN PHARMA mainly business includes: 1) API, Pharmaceutical Intermediates, CMO, CRO, CDMO and so on. 2) Pharmaceutical Equipment such as: Distilled Water Machinery, Mixer, Sterilizer and so on.

    JINLAN PHARM focus on:

    ■ Contrast Agent

    ■ Anti-COVID APIs

    ■ Respiratory System APIs

    ■ Anti-tumor & Anti-Cancer APIs

    ■ Anti-Diabetes APIs

    ■ Anti-HCV & Anti-HBV APIs

    ■ Anti-HIV APIs

    ■ Peptides

    ■ Pharmaceutical Intermediates

    ■ CMO, CRO, CDMO

  • Country Product Purchase Quantity Date Posted
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.